Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, ...

If you missed the early fall push for flu and COVID-19 vaccines, it's not too late. Health officials say it's important to ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...

Please report side effects. See the full CMI for further details. 1. Why am I being given COMIRNATY Omicron XBB.1.5? COMIRNATY Omicron XBB.1.5 is a vaccine given to prevent coronavirus disease ...

Please report side effects. See the full CMI for further details. 1. Why am I being given COMIRNATY JN.1? COMIRNATY JN.1 is a vaccine given to prevent coronavirus disease 2019 (COVID-19 ...